Global /United States /Healthcare /Biotechnology /ALLK

Allakos Inc.

ALLK

• NASDAQ: ALLK • Delayed

0.3291USD 0%

As of 13 June 2026, Allakos Inc. has a market cap of $29.74M USD, ranking #34299 globally and #4794 in the United States. It ranks #3094 in the Healthcare sector, and #595 in the Biotechnology industry.

Global Rank

34299

Country Rank

4794

Sector Rank

3094

Industry Rank

595

Key Stats

Market Cap

$29.74MUSD

Enterprise Value

-$25.49MUSD

EBITDA (TTM)

-$88.89MUSD

Net Income (TTM)

-$70.85MUSD

PB Ratio

0.5

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Robert Alexander open_in_new

Employees

131

Founded

2012

IPO

19 Jul 2018

Website

allakos.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	0.4%	2.7%	5.2%	-72%	-73%	-72%	-90%	-99%

News

ALLK Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	ALLK Allakos Inc ISIN: US01671P1003 Shares Out.: Shares Outstanding: 90.377M¹ Shares Float: 76.028M² TV: TradingView: NASDAQ: ALLK SA: Stock Analysis: NASDAQ: ALLK YF: Yahoo Finance: ALLK GF: Google Finance: NASDAQ: ALLK NQ: NASDAQ: ALLK BA: Barron's: ALLK MS: Morningstar: XNAS: ALLK	0.3291 USD	TV: TradingView: NASDAQ: ALLK SA: Stock Analysis: NASDAQ: ALLK YF: Yahoo Finance: ALLK GF: Google Finance: NASDAQ: ALLK NQ: NASDAQ: ALLK BA: Barron's: ALLK MS: Morningstar: XNAS: ALLK

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Allakos Inc.

Allakos Inc., a clinical stage biotechnology company, engages in the development of therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 613K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 538K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 93K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 88K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 84K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 61K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 161K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 151K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 142K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 142K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 94K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 86K%	-	Germany

chevron_leftBack